Travere Therapeutics financials
$59.99−2.57%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $490.7M | $233.2M | $145.2M | $109.5M | $131.8M | $198.3M |
| Gross profit | $480.4M | $225.4M | $133.8M | $105.0M | $128.0M | $192.2M |
| Gross margin | 97.9% | 96.7% | 92.1% | 96.0% | 97.1% | 96.9% |
| Operating income | -$62.8M | -$323.8M | -$388.1M | -$319.8M | -$199.4M | -$176.2M |
| Net income | -$25.5M | -$321.5M | -$111.4M | -$278.5M | -$180.1M | -$169.4M |
| Net margin | −5.2% | −137.9% | −76.7% | −254.4% | −136.6% | −85.4% |
| Diluted EPS | $-0.29 | $-4.08 | $-1.50 | $-4.37 | $-3.01 | $-3.56 |
| EBITDA | -$2.1M | -$277.8M | -$338.2M | -$299.1M | -$186.7M | -$151.6M |
| Operating cash flow | $37.8M | -$237.5M | -$280.0M | -$186.3M | -$14.8M | -$42.7M |
| Free cash flow | $37.8M | -$302.5M | -$280.0M | -$186.3M | -$19.9M | -$49.5M |
| Diluted shares | 89.2M | 78.9M | 74.3M | 63.8M | 59.8M | 47.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $93.0M | $58.5M | $58.2M | $61.7M | $165.8M | $84.8M |
| Short-term investments | $229.8M | $312.2M | $508.7M | $388.6M | $387.1M | $276.8M |
| Total debt | $311.7M | $379.0M | $377.3M | $375.5M | $226.6M | $215.3M |
| Total assets | $605.2M | $594.1M | $788.9M | $672.6M | $776.6M | $607.4M |
| Total liabilities | $490.4M | $535.0M | $588.1M | $629.7M | $474.5M | $396.2M |
| Shareholders' equity | $114.8M | $59.1M | $200.8M | $42.9M | $302.1M | $211.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology